FDA approves noninvasive Optune Pax device for advanced pancreatic cancer

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of Optune Pax was granted to Novocure.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup